BI 764532
Boehringer Ingelheim
['lung']
martin wermke on first-in-human dose-escalation trial of bi 764532, a delta-like ligand 3/cd3 igg-like t-cell engager, in patients with dll3-positive small-cell lung cancer and neuroendocrine carcinoma #asco23 
Associate Scientific Director, Computational Biology Oncology at @boehringer 🧬 Data Scientist & KRAS, MDM2 , HER2 Research. Tweets are my own.